Due to LSD-1 being implicated in several cancers, LSD-1 inhibitors, many of which are derived from monoamine oxidase (MAO) inhibitors owing to their structural similarity, have been developed as a therapeutic modality [74,75,76]. The gene discussed is KDM1A; the disease is cancer.